|
Former Executive Director, MIT Center for Biomedical Innovation; Professor of the Practice jointly in the MIT School of Engineering, MIT Sloan School of Management, MIT School of Science, and the Harvard-MIT Division of Health Sciences & Technology
Dr. Douglas is recognized for his leadership and involvement at the Massachusetts Institute of Technology (MIT), where he was active until his departure in July 2007. He established and led the Center for Biomedical Innovation Management at MIT, was a Professor of Practice for the MIT School of Engineering, the MIT Sloan School of Management, the MIT School of Science and the Harvard-MIT Division of Health Sciences and Technology.
From 1992 until his corporate retirement in 2004, Dr. Douglas held key management roles with several global pharmaceutical companies, including; Executive Vice President, Drug Innovation and Approval, and Chief Scientific Officer for Aventis Pharma AG (1999-2004), Executive Vice President and Head of Global Research and Development at Hoechst Marion Roussel (1995-1999) which merged with Rhone Poulenc Rorer to from Aventis S.A., and Executive Vice President of Global Research & Development for Marion Merrell Dow (1992-1995). Over this span of 22 years in the pharmaceutical industry, Dr. Douglas led the discovery, development, and market introduction and life cycle management of more than 20 drugs, including Allegra, Actonel, Anzemet, Taxotere, Lantus and Exubera.
| 